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Previously, we have shown that transforming growth factor b 1 (TGFb1) overexpression in suprabasal epidermis
suppresses skin carcinogenesis at early stages, but promotes tumor invasion at later stages. To elucidate the role
of TGFb1 overexpression in naturally occurring human squamous cell carcinomas (SCC), we screened TGFb1
expression patterns in human skin SCC samples and found that TGFb1 was overexpressed with two distinct
patterns: either predominantly in suprabasal layers or throughout tumor epithelia including basal proliferative
cells. To determine the effect of TGFb1 overexpression in basal keratinocytes, we generated transgenic mice
expressing wild-type TGFb1 in basal keratinocytes and hair follicles using the K5 promoter (K5.TGFb1wt). Surpris-
ingly, these mice developed a severe inﬂammatory skin disorder. Inﬂammation was also observed in head and neck
tissue when TGFb1 transgene expression was inducibly expressed in head and neck epithelia in our gene-switch-
TGFb1 transgenic mice. Given the importance of inﬂammation in cancer development, our data suggest that TGFb1-
induced inﬂammation may override its tumor-suppressive effect even at early stages of skin carcinogenesis. This
notion is further suggested by our recent study that Smad3 knockout mice were resistant to skin chemical car-
cinogenesis at least in part via abrogation of endogenous TGFb1-induced inﬂammation.
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Transforming Growth Factor b (TGFb)
Signaling
TGFb represents a family of pluropotent cytokines that
consist of three isoforms in mammals including TGFb1, -2,
and -3, with TGFb1 being the predominant one in most tis-
sue types including the skin (Wang, 2001; Li et al, 2003).
TGFb1 plays a pivotal role in the maintenance of tissue
homeostasis by regulating cell growth, differentiation, ex-
tracellular matrix deposit, immune/inflammatory responses,
and angiogenesis (for recent reviews, see Derynck and
Zhang, 2003a; Siegel and Massague, 2003). TGFb1 is syn-
thesized and secreted in a latent form (TGFb1wt), in which
the N-terminal latency-associated peptide (LAP) remains
non-covalently bound to the C-terminal mature TGFb1. The
mature TGFb1 is cleaved from the LAP following proteolysis
and becomes a functionally active form (TGFb1act) (Law-
rence, 1991). Constitutive activation of TGFb1 has been
achieved by two site-specific mutations in the LAP, Cys-
223 ! Ser, and Cys-225 ! Ser (TGFb1S223/225), which
prevent the LAP from binding to the mature TGFb1 (Brun-
ner et al, 1989). TGFb functions through a signaling cascade
that is elicited when TGFb ligands (TGFb) bind to the spe-
cific membrane-bound kinase type I and type II TGFb re-
ceptor complex (TGFbRI, TGFbRII, Fig 1, for recent reviews,
see Miyazawa et al, 2002; Derynck and Zhang, 2003a; Re-
guly and Wrana, 2003; Shi and Massague, 2003). Although
several subtypes of TGFbRI have been identified, to date,
only one TGFbRII has been identified, which is essential for
TGFb binding and for assembly of the TGFbRI–TGFbRII
complex (Derynck and Zhang, 2003b). When TGFb binds
to a TGFbRI–TGFbRII complex, the classic TGFbRI, also
known as activin receptor-like kinase-5 (ALK5), phosphory-
lates two receptor-specific Smads (R-Smads); Smad2 and
Smad3. Phosphorylated Smad2 and Smad3 form het-
eromeric complexes with the common Smad, Smad4, and
translocate into the nucleus to regulate TGFb-responsive
genes (Derynck and Zhang, 2003b). Smad2/Smad3 activa-
tion mediates TGFb1-induced growth inhibition on epithelial
and endothelial cells (Goumans et al, 2003a, b) and growth
promotion on mesenchymal cells (such as fibroblasts) (Pit-
telkow, 1992). Another TGFbRI, ALK1, has been recently
identified to be preferentially expressed in endothelial cells
(Fig 1). Activated ALK1 phosphorylates and activates two
other R-Smads, Smad1 and Smad5, which positively reg-
ulate endothelial cell proliferation and migration (Goumans
et al, 2003a, b). In this context, endoglin, a transmembrane
glycoprotein that is also mainly expressed by endothelial
cells, may function as an accessory molecule to facilitate
Abbreviations: ALK, activin receptor-like kinase; Id, inhibitor of dif-
ferentiation; IFN-g, interferon-g; IL, interleukin; KGF, keratinocyte
growth factor; MCP, monocyte-chemotactic protein; MIP, ma-
crophage inflammatory protein; MMP, matrix metalloproteinase; R-
Smads, receptor-specific Smads; SBE, Smad-binding element;
SCC, squamous cell carcinomas; TGFb, transformation growth
factor b; TGFbRI, type I TGFb receptor; TGFbRII, type II TGFb
receptor; TNF-a, tumor necrosis factor-a; VEGF, vascular end-
othelial growth factor
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TGFb ligand and receptor interaction (Fig 1, Cheifetz et al,
1992; Yamashita et al, 1994). Two inhibitory Smad proteins,
Smad6 and Smad7, can be rapidly induced by TGFb, which
then block TGFb signaling by competing with R-Smads for
interaction with the activated type I receptors, thereby in-
hibiting R-Smad phosphorylation by competing with Smad4
for heteromeric complex formation with phosphorylated R-
Smads or by recruiting ubiquitin ligases to the activated
receptors to induce their degradation via proteosomal and
lysosomal pathways (Fig 1) (Imamura et al, 1997; Afrakhte
et al, 1998; Schiffer et al, 2002).
Paradoxical Role of TGFb1 in Skin
Carcinogenesis
TGFb1 is overexpressed in both early and late stages in
many human cancer types (Reiss, 1997; Gold, 1999). Stud-
ies have shown that TGFb1 plays a dual role in skin car-
cinogenesis. When TGFb1 transgene is targeted primarily
in the suprabasal/differentiated layers of the epidermis in
transgenic mice, TGFb1 overexpression inhibits papilloma
formation at early stages but promotes tumor progression,
metastasis, and epithelial–mesenchymal transition at later
stages of skin carcinogenesis (Cui et al, 1995, 1996; Weeks
et al, 2001). The earlier tumor-suppressive role of TGFb1 is
attributed to its growth-inhibitory effect on keratinocytes,
whereas the later tumor promotion role is associated with its
effects on loss of epithelial cell adhesion, extracellular ma-
trix remodeling, and enhanced angiogenesis (Weeks et al,
2001). The current view of the role of TGFb1 in carcinogen-
esis is that its tumor-suppressive effect is dominant at early
stages, whereas its tumor-promoting effect is dominant
at later stages of carcinogenesis (Roberts and Wakefield,
2003). Recent studies, however, have begun to challenge
this point of view. When TGFb1 transgene is expressed in
proliferative keratinocytes of the epidermis and hair follicles
using either a keratin K5 or K14 promoter, the preneoplastic
transgenic skin exhibits many pathological alterations re-
quired for tumor promotion. These include severe inflam-
mation, angiogenesis, basement membrane degradation,
and surprisingly, epidermal hyperproliferation as a result
of inflammation and angiogenesis (Liu et al, 2001; Li et al,
2004b). These data suggest that TGFb1 overexpression
may have a tumor-promoting effect even at the early stages
of skin carcinogenesis if it is overexpressed in proliferative
cells of the epidermis/tumor epithelia. Interestingly, when
we performed in situ hybridization to examine TGFb1 ex-
pression patterns in human skin squamous cell carcinomas
(SCC), we observed two patterns with a similar ratio of
occurrence: either predominantly in suprabasal layers or
throughout tumor epithelia including basal proliferative cells
(Fig 2). The epidermis adjacent to SCC exhibited TGFb1
expression patterns similar to the corresponding tumors
(Fig 2). These two TGFb1 expression patterns did not cor-
relate with the differentiation states of SCC. To date, it is not
clear whether the specific locations of TGFb1 expression
differentially affect tumor progression.
Role of TGFb1 in Skin Inﬂammation
TGFb1 has both positive and negative effects on the reg-
ulation of inflammation and immune response, depending
on the state of differentiation of the cells and the cytokine
milieu (Wahl, 1994; Letterio and Roberts, 1998; Ludviksson
et al, 2000; Prud’homme and Piccirillo, 2000). The anti-in-
flammatory and immunosuppressive effect of TGFb1 has
been excessive as TGFb1 knockout mice spontaneously
develop multifocal inflammation and autoimmune disorders
(Shull et al, 1992; Kulkarni et al, 1993). These knockout
mice, however, do not develop any skin inflammatory phe-
notypes, suggesting that the action of TGFb1 in the context
of inflammation may vary depending on different tissue
types. Further characterization of TGFb1 knockout mice re-
vealed a lack of Langerhans cells in TGFb1 knockout ep-
idermis (Borkowski et al, 1996, 1997), and a dysfunction of
dermal dendritic cells in terms of trafficking antigens to re-
gional lymph nodes (Hemmi et al, 2001). These findings
highlight the role of TGFb1 in the maturation of skin-homing
dendritic cells, which is crucial for triggering inflammatory
and immune response upon various stimuli.
Using a transgenic approach, we have shown that
K5.TGFb1wt transgenic mice, with the TGFb1 expression
Figure 1
Schematic of transforming growth factor b 1 (TGFb1)-elicited sig-
nal transduction pathway. In most cell types such as keratinocytes
and fibroblasts, the classic type I TGFb receptor (TGFbRI), activin re-
ceptor-like kinase-5 (ALK5), is expressed and its activation upon TGFb1
interacting with type II TGFb receptor (TGFbRII) leads to phosphorylat-
ion of two receptor-specific Smads (R-Smads); Smad2 and Smad3
(pSmad2/3). Endothelial cells express both ALK5 and ALK1. Upon ac-
tivation of ALK1, it phosphorylates another two R-Smads; Smad1 and
Smad5 (pSmad1/5). The phosphorylated R-Smads then bind to Smad4
to form a protein complex that undergoes a nuclear translocation to
regulate different downstream TGFb1-responsive genes by binding to
the Smad-binding element (SBE). Typically, expression of plasminogen
activator inhibitor (PAI)-1 is mediated by pSmad2/3, whereas pSmad1/
5 is responsible for the expression of inhibitor of differentiation (Id)-1.
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level similar to the peak level during cutaneous wound
healing in normal mice, spontaneously develop skin phe-
notypes that are strikingly similar to psoriasis in humans (Li
et al, 2004b). By 3 mo of age, K5.TGFb1wt skin developed
focal erythematous plaques with a scaly appearance, which
are similar to psoriatic plaques in humans (Fig 3). As skin
inflammation progresses, the entire K5.TGFb1wt skin be-
comes scaly and erythematous, the gross appearance of
which closely resembles psoriatic erytheroderma in humans
(Fig 3).
Prior to the development of overt psoriatic lesions,
K5.TGFb1wt transgenic mice remain macroscopically indis-
tinguishable from non-transgenic littermates until about
1 mo of age. Skin inflammation and angiogenesis, however,
have already been noticeable histologically as early as day
10 post-partum (p.p.). Gradually, inflammatory cell infiltra-
tion becomes profound at day 17 (Fig 4) and the ne-
ovascularization reaches a peak around day 24 p.p. (Li et al,
2004b), prior to the development of epidermal hyperplasia.
Interestingly, aberrant K6 expression in the interfollicular
epidermis, usually a marker for hyperplastic epidermis, is
observed in day 17 transgenic skin (Fig 4). This dynamic of
pathological changes in K5.TGFb1wt skin suggests that ep-
idermal hyperplasia is the secondary effect of inflammation
and angiogenesis. When we cultured transgenic keratin-
ocytes in the absence of other cell types, transgenic ker-
atinocytes underwent growth arrest (Li et al, 2004b). This
result further indicates that transgenic keratinocytes by
themselves are not sufficient to overcome the growth-in-
hibitory effect by TGFb1. It is thus likely that the inflamma-
tory cytokines (e.g., interleukin 1 (IL-1)), chemokines (e.g.,
macrophage inflammatory protein (MIP-2)), growth factors
(e.g., keratinocyte growth factor (KGF)), and angiogenic
factors (e.g., vascular endothelial growth factor (VEGF))
produced by inflammatory cells and/or hyperproliferative
fibroblasts (Fig 4), together with growth regulators (e.g.,
amphiregulin) produced by keratinocytes themselves (au-
tocrine effect), are able to provide strong mitogenic signals
and to override TGFb1-induced growth inhibition on the
epidermis in vivo (Li et al, 2004b). Previous transgenic
models overexpressing genes encoding the above-men-
tioned molecules individually in keratinocytes have also
shown epidermal hyperproliferation to varying degrees
(Schon, 1999). Interestingly, in vivo epidermal hyperprolifer-
ation in K5.TGFb1wt mice does not require a loss of TGFb
responsiveness in keratinocytes, which often occurs in
tumors cells as transgenic keratinocytes attest a normal
TGFb/Smad signaling process (Li et al, 2004b).
Psoriasis-like phenotypes in adult K5.TGFb1wt mice are
characterized by prominent epidermal hyperplasia, massive
Figure 2
In situ hybridization of transforming
growth factor b 1 (TGFb1) in human skin
squamous cell carcinomas (SCC) and
adjacent epidermis. The dotted lines de-
lineate the boundary between the basal
layer of the epidermis and the dermis of
skin adjacent to SCC, and between tumor
epithelia and the stroma. (A, C) TGFb1
transcripts were predominant in the sup-
rabasal layers of the epidermis (A) and
tumor epithelia (C). (B, D) TGFb1 tran-
scripts were also found to be present
throughout the adjacent epidermis (B) and
tumor epithelia (D) (left lobule of the SCC)
or predominantly in the basal layer of
tumor epithelia (right lobule of the SCC).
The dermis and tumor stroma also express
a weaker level of TGFb1. (E, F) A hem-
atoxylin & eosin (H&E) section (E) shows a
typical SCC lobule surrounded by the
stroma, and the sense probe control of in
situ hybridization (F) displays little back-
ground staining. The bar represents 40 mm
for all sections.
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inflammatory cell infiltration, and increased angiogenesis (Li
et al, 2004b). The numerous inflammatory cells in transgenic
skin include T cells (with CD4þ cells mainly in the dermis
and CD8þ cells predominantly in the epidermis), mon-
ocytes/macrophages, neutrophils, as well as mast cells fit-
ting the scope of leukocytes that respond toward the strong
chemotactic effect of TGFb1 (Wahl et al, 1987; Wahl, 1992,
1994, 1999; Bonifati and Ameglio, 1999). The skin inflam-
matory phenotypes are associated with an upregulation in a
variety of genes encoding inflammatory cytokines (e.g., IL-
1, IL-2, tumor necrosis factor a (TNF-a), and interferon (IFN)-
g), chemokines (e.g., MIP-2 (murine counterpart of IL-8),
monocyte-chemotactic protein (MCP)-1, and IFN-induced
protein-10), growth regulators (e.g., insulin-like growth fac-
tor, amphiregulin, and KGF), matrix metalloproteinases
(MMP) (e.g., MMP-2, -3, and -9), and angiogenic factors
(e.g., VEGF) and their receptors (e.g., Flt-1 and Flk-1) (Li
et al, 2004b), all of which have been reported to be unreg-
ulated in human psoriatic lesions (Christophers, 1996; Cook
et al, 1997; Christophers and Mrowietz, 1998; Bonifati and
Ameglio, 1999). Our data suggest that TGFb1 functions as
an initiator or coordinator during psoriasis development by
inducing or recruiting multiple pro-inflammatory molecules
produced by various cell types. This complex cascade is
depicted in Fig 5. Consistent with our study, recent clinical
studies have reported that increased TGFb1 levels in
psoriatic lesions and sera of psoriatic patients correlate
with disease severity or duration (Flisiak et al, 2002).
TGFb1-Associated Inﬂammation in Skin
Carcinogenesis
Inflammation plays a paradoxical role in cancer develop-
ment. Inflammatory cells produce cytokines and chemo-
kines, which initiate cancer immunity (Coussens and Werb,
Figure 3
Comparison of skin phenotypes in
K5.TGFb1wt mice (A, C, E) and psoriatic
lesions in humans (B, D, F). The focal
erythematous plaques with a scaly appear-
ance in a 3-mo-old K5.TGFb1wt mouse
(A) resembled human psoriatic plaques
(B). As the disease progressively wors-
ens, K5.TGFb1wt mice develop generalized
scaly erythemas (C), reminiscent of psoria-
tic erythroderma in humans (D). Histology
shows that K5.TGFb1wt skin (E) has a mor-
phology similar to human psoriasis lesion
(F). (A) and (C) were reproduced from our
previous work (Li et al, 2004b) with the
permission of the Nature Publishing Group.
(B), (D), and (F) were reproduced from Fig-
ure 43-1-B and Figure 43-10-A, respec-
tively, of Christophers and Mrowietz (1998)
with the permission of the McGraw-Hill
Companies. TGFb1, transforming growth
factor b 1.
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2002). On the other hand, many inflammatory cytokines and
chemokines also stimulate cell proliferation and angiogen-
esis, which facilitate tumor growth (Coussens and Werb,
2002; Vicari and Caux, 2002). In addition to inflammatory
cells, virtually all cells, including many tumor cell types, ex-
press inflammatory cytokines, chemokines, and their re-
ceptors (Coussens and Werb, 2002; Vicari and Caux, 2002).
Certain chemokines and their receptors promote cellular
transformation and mediate metastasis formation via a
mechanism similar to chemokine-mediated leukocyte trans-
port (Vicari and Caux, 2002; Sparmann and Bar-Sagi, 2004).
With respect to skin cancer, paradoxical effects of inflam-
mation on cancer development have also been reported.
Psoriasis patients with chronic skin inflammation do not
show increased skin cancer development from the psoriatic
plaques (Nickoloff, 2004). In contrast, an interesting report
provided evidence for an association between inflammation
and progression of actinic keratoses to SCC in humans
(Berhane et al, 2002). SCC arising in connection with chron-
ic venous leg ulcers also appear aggressive and have a high
propensity to metastasize (Baldursson et al, 1999). In ex-
perimental skin cancer, wounding, which elicits an inflam-
matory response, has long been known to enhance cancer
development (Wang et al, 1995), and most classical tumor
promoters, including 12-O-tetradecanoylphorbol-13-ace-
tate (TPA), induce inflammation (Patamalai et al, 1994).
Conversely, in a human papillomavirus oncogene-induced
skin carcinogenesis model, mice devoid of pro-inflamma-
tory CD4þ Tcells exhibit a lower incidence of tumors and a
delayed neoplastic progression (Daniel et al, 2003). In ad-
dition, anti-inflammation drugs, e.g., non-sterol anti-inflam-
matory drugs, exert both chemopreventive and therapeutic
effects on UV-induced skin cancer in mice (Fischer, 2002;
Fischer et al, 2003).
To assess the role of TGFb1-associated inflammation in
carcinogenesis, we turned our attention to head and neck
SCC (HNSCC). In comparison with skin SCC, HNSCC more
frequently develop from the site of chronic inflammation
(e.g., oral lichen planus) and have a much worse prognosis
(Coussens and Werb, 2002; Philpott and Ferguson, 2004).
We found that TGFb1 protein is increased in about 80% of
human HNSCC, ranging from a 1.5- to 7.5-fold increase in
Figure 4
Inflammation and angiogenesis pre-
cedes epidermal hyperplasia in
K5.TGFb1wt skin. N, non-transgenic
littermates, Tg, transgenic mice. The
bar in the first panel of (A) represents
40 mm for all sections. (A) Transgenic
mice do not show epidermal hyperl-
asia at day 17 as compared with non-
transgenic littermates. A K14 antibody
was used as a counterstaining for
immunofluorescence. Skin samples
were harvested from day 17 transgenic
mice and non-transgenic littermates
with 0.125 mg per g BrdU injected 2 h
prior to sacrifice. Hematoxylin & eosin
(H&E) and immunofluorescence dem-
onstrated that the epidermal thickness
and the number of BrdU-labeled ker-
atinocytes (short arrow in BrdU stain-
ing panel) in day 17 transgenic
epidermis were similar to those of
non-transgenic littermates. Transgenic
skin exhibited an aberrant K6 expres-
sion in the interfollicular epidermis in
addition to the normal staining pattern
in hair follicle epithelia. Note the scat-
tered BrdUþ fibroblasts (long arrows
in BrdU staining panel) in transgenic
but not in non-transgenic dermis. Neovascularization is obvious (open arrows in H&E panel)
in transgenic skin. (B) Day 17 transgenic skin exhibits prominent inflammatory cell infiltration.
Hematoxylin was used as a counterstaining. Immunohistochemistry revealed significantly
increased CD45þ cells, CD4þ lymphocytes (mainly in the dermis), CD8þ lymphocytes
(predominantly in the epidermis), BM8þ macrophages, CD103þ cells (exclusively in the
epidermis), Ly-6Gþ granulocytes, and mast cells in transgenic skin in comparison with non-
transgenic skin. The dotted lines delineate the boundary between the epidermis and the
dermis. Representative inflammatory cells are shown in the epidermis (red arrows) and the
dermis (black arrows). The figure is reproduced from our previous work (Li et al, 2004b) with
the permission of the Nature Publishing Group, with the exception of Ly-6G staining in (B).
TGFb1, transforming growth factor b 1.
114 LI ET AL JID SYMPOSIUM PROCEEDINGS
comparison with the endogenous TGFb1 in normal epithelia
(Lu et al, 2004). Moreover, TGFb1 is overexpressed at the
preneoplastic lesions adjacent to HNSCC, relative to unin-
volved mucosa from the same patient (Lu et al, 2004), sug-
gesting that TGFb1 overexpression is an early event during
HNSCC development. To further determine whether early-
stage TGFb1 overexpression directly induces inflammation,
we induced TGFb1 transgene expression in head and neck
epithelia in our keratinocyte-specific gene-switch trans-
genic mice. As shown in Fig 6, this system consists of a
transactivator (K5.GLp65) transgenic line and a downstream
target line (tata.TGFb1). In K5.GLp65 transgene, the trans-
activation domain of nuclear factor-kB (NF-kB) subunit p65
is fused to the yeast GAL4 transcription factor and the
truncated ligand-binding domain of the progesterone re-
ceptor (DPR). The DPR does not bind to endogenous pro-
gesterone, but binds to progesterone antagonists, such as
RU486, which initiates a nuclear translocation of the p65
fusion protein and activates the target gene. The promoter
of the target transgene tata.TGFb1 has been specifically
engineered to contain four copies of the yeast GAL4-bind-
ing element, which can be recognized by the GAL4 protein
within the p65 fusion protein (Lu et al, 2004). TGFb1 over-
expression in head and neck epithelia or the epidermis can
be induced upon topical application of RU486 to bigenic
mice (K5.GLp65/tata.TGFb1) (Fig 6). Similar to the effect of
TGFb1 overexpression in the epidermis (Li et al, 2004b), we
found that TGFb1 transgene induction in oral mucosa also
results in inflammation, increased angiogenesis, and sub-
sequent epithelial hyperproliferation (Lu et al, 2004). This
result argues whether TGFb1 overexpression at early stages
of HNSCC development would provide any tumor-suppres-
sive effect.
In the two-stage skin carcinogenesis model, TPA rapidly
induces TGFb1 expression in keratinocytes (Patamalai et al,
1994). Therefore, if inflammation is a direct effect of en-
dogenous TGFb1 overexpression, it may contribute greatly
to the tumor promotion effect of TGFb1. This notion is sup-
ported by our recent finding that mice lacking Smad3, the
major intracellular mediator for TGFb1-mediated signaling,
exhibit a resistance to cancer formation during the two-
stage chemical carcinogenesis experiment (Li et al, 2004a).
In this study, we applied 7,12-dimethylbenz[a]anthracene-
initiation and TPA-promotion protocol to homozygous and
heterozygous Smad3 knockout (Smad3/, Smad3þ /)
mice, and wild-type (Smad3þ /þ ) mice. Both Smad3/
and Smad3þ / mice showed a significant reduction in
papilloma formation and malignant conversion in compar-
ison with wild-type mice (Li et al, 2004a). These data sug-
gest that impaired TGFb signaling affects both early (benign
tumor formation) and late (tumor progression and metasta-
sis) stages of skin carcinogenesis. In other words, TGFb1
may promote tumor development even in the earlier stage
Figure 5
Mechanisms of transforming growth factor b 1 (TGFb1)wt overex-
pression-induced psoriasis-like phenotypes. The underlined events
are essential for the development of psoriasis-like phenotypes in
K5.TGFb1wt mice. TGFb1 itself is a potent chemoattractant for le-
ukocytes, and can recruit them to the skin. Matrix metalloproteinases
(MMP) are upregulated in keratinocytes and mediate basement mem-
brane (BM) degradation. This facilitates TGFb1 secretion into the de-
rmis where it stimulates fibroblast proliferation and further enhances
leukocyte infiltration. Growth factors produced by hyperproliferative
fibroblasts feed back to the overlying keratinocytes, causing epidermal
hyperproliferation and hyperplasia. In addition to angiogenic factors
(e.g., vascular endothelial growth factor (VEGF)) produced by kera-
tinocytes and inflammatory cells, TGFb1 itself directly stimulates
angiogenesis. Furthermore, interleukin (IL)-1 release by impaired
keratinocytes initiates the inflammatory cascade in the skin, thus lead-
ing to the production of an array of inflammatory cytokines (especially
the primary pro-inflammatory cytokines, IL-1 and tumor necrosis factor
a (TNF-a)), chemokines, and other inflammatory mediators that result in
deteriorated and unresolved inflammation. Together, these events con-
fer a progressive psoriasis-like skin inflammatory disorder.
Figure6
Schematic of gene-switch-TGFb1wt transgenic mice. (A) The gene-
switch transgenic system contains two transgenic lines; the transac-
tivator line (K5.GLp65) and the target line (tata.TGFb1). Driven by a K5
promoter, the transactivator line overexpresses a fusion protein includ-
ing the yeast transcription factor GAL4 protein, the truncated ligand-
binding domain of progesterone receptor (DPR), and the transactivation
domain of NF-kB subunit p65. The transgene of the target line cannot
be expressed by itself, as the TGFb1 cDNA is under the control of a
minimal tata promoter sequence that is fused with four copies of yeast
GAL-binding element. TGFb1 overexpression can be induced only in
the squamous epithelia (e.g., oral mucosa or dorsal skin) of bigenic
mice by progesterone antagonists such as RU486. (B). RU486 binds to
DPR and leads the p65 fusion protein to translocate to the nucleus,
where it binds to the promoter of the target transgene and activates the
transcription of TGFb1.
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of skin carcinogenesis. The resistance of Smad3 knockout
mice to skin carcinogenesis is attributed to the reduction of
AP-1 family members that are TGFb responsive genes and
play an important role in tumor promotion, and reduced in-
flammation in Smad3 knockout skin/tumors as compared
with wild-type skin/tumors (Li et al, 2004a). In particular,
Smad3 knockout papillomas contain fewer tumor-associat-
ed macrophages, which correlates with a reduction in ex-
pression of IL-1, a primary inflammatory cytokine, and of
MCP-1, a strong chemoattractant for monocytes/macroph-
ages, as compared with wild-type papillomas. Consistently,
Smad3 knockout tumors exhibit decreased activation of the
NF-kB pathway, the central signaling controlling tumor-as-
sociated inflammation (Li et al, 2004a). Thus, this study
suggests that, at early stages of skin carcinogenesis,
TGFb1 overexpression induced by TPA may have a tumor-
promoting effect, via activation of AP-1 family members in
keratinocytes and inflammation in the stroma, both of which
may require wild-type Smad3.
In summary, our recent studies suggest that the effect of
TGFb1 on carcinogenesis largely depends on its cell-spe-
cific expression pattern. When TGFb1 is overexpressed in
proliferative keratinocytes, it induces profound inflammation
that is sufficient to override its growth-inhibitory effect.
Thus, our studies instigate future investigation of the role of
TGFb1 overexpression-associated inflammation in cancer
development and its underlying molecular mechanisms.
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